These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30926960)

  • 1. Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth.
    Tamura RE; Lana MG; Costanzi-Strauss E; Strauss BE
    Gene Ther; 2020 Feb; 27(1-2):15-26. PubMed ID: 30926960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector.
    Tamura RE; Hunger A; Fernandes DC; Laurindo FR; Costanzi-Strauss E; Strauss BE
    Hum Gene Ther; 2017 Aug; 28(8):639-653. PubMed ID: 28181816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy.
    Tamura RE; da Silva Soares RB; Costanzi-Strauss E; Strauss BE
    Cancer Biol Ther; 2016 Dec; 17(12):1221-1230. PubMed ID: 27646031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
    Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
    Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
    Mukhtar E; Adhami VM; Siddiqui IA; Verma AK; Mukhtar H
    Mol Cancer Ther; 2016 Dec; 15(12):2863-2874. PubMed ID: 27765854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
    Eastham JA; Grafton W; Martin CM; Williams BJ
    J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals.
    Xie H; Li C; Dang Q; Chang LS; Li L
    Oncotarget; 2016 Jan; 7(2):1341-53. PubMed ID: 26625310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
    Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
    Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
    Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.
    Yoo GH; Piechocki MP; Oliver J; Lonardo F; Zumstein L; Lin HS; Kim H; Shibuya TY; Shehadeh N; Ensley JF
    Laryngoscope; 2004 Nov; 114(11):1871-9. PubMed ID: 15510008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.
    Ko SC; Gotoh A; Thalmann GN; Zhau HE; Johnston DA; Zhang WW; Kao C; Chung LW
    Hum Gene Ther; 1996 Sep; 7(14):1683-91. PubMed ID: 8886839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.
    Symes JC; Kurin M; Fleshner NE; Medin JA
    Mol Cancer Ther; 2008 Sep; 7(9):3018-28. PubMed ID: 18790782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.
    Singh PP; Joshi S; Russell PJ; Verma ND; Wang X; Khatri A
    Clin Cancer Res; 2011 Jun; 17(12):4006-18. PubMed ID: 21531822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells.
    Zhang S; Wang Y; Chen Z; Kim S; Iqbal S; Chi A; Ritenour C; Wang YA; Kucuk O; Wu D
    Prostate; 2013 Nov; 73(15):1681-9. PubMed ID: 23999913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.